keyword
MENU ▼
Read by QxMD icon Read
search

Brodalumab

keyword
https://www.readbyqxmd.com/read/27856660/effect-of-il-17-receptor-a-blockade-with-brodalumab-in-inflammatory-diseases
#1
REVIEW
Ajay Nirula, Jon Nilsen, Paul Klekotka, Greg Kricorian, Ngozi Erondu, Jennifer E Towne, Chris B Russell, David A Martin, Alison L Budelsky
IL-17 cytokines are expressed by a variety of cells and mediate host defence against extracellular pathogens. IL-17 is upregulated at sites of inflammation and can synergize with other cytokines, such as TNF-α, to amplify the inflammatory response. Activation of these signalling pathways has been hypothesized to contribute to the underlying pathogenesis of several inflammatory diseases, including psoriasis, RA, PsA and asthma. Thus the IL-17 signalling pathway is an attractive target for the development of therapeutic agents to modulate aberrant inflammatory responses...
December 2016: Rheumatology
https://www.readbyqxmd.com/read/27836567/management-of-psoriatic-arthritis-early-diagnosis-monitoring-of-disease-severity-and-cutting-edge-therapies
#2
REVIEW
Siba P Raychaudhuri, Reason Wilken, Andrea C Sukhov, Smriti K Raychaudhuri, Emanual Maverakis
Psoriatic arthritis (PsA) is a heterogeneous disease that can involve a variety of distinct anatomical sites including a patient's peripheral and axial joints, entheses, skin and nails. Appropriate management of PsA requires early diagnosis, monitoring of disease activity, and utilization of cutting edge therapies. To accomplish the former there are a variety of PsA-specific tools available to screen, diagnose, and assess patients. This review will outline the recently developed PsA screening tools, including the Toronto Psoriatic Arthritis Screening Questionnaire (TOPAS), the Psoriasis Epidemiology Screening Tool (PEST), the Psoriatic Arthritis Screening and Evaluation (PASE), and the Psoriasis and Arthritis Screening Questionnaire (PASQ)...
November 8, 2016: Journal of Autoimmunity
https://www.readbyqxmd.com/read/27826996/treatment-of-psoriatic-arthritis-with-traditional-dmard-s-and-novel-therapies-approaches-and-recommendations
#3
Ajesh B Maharaj, Vinod Chandran
Recent advances in the therapeutics of psoriatic arthritis (PsA) have provided more options to clinicians managing PsA. The purpose of this review is to update the reader on treatment options for PsA using conventional synthetic disease modifying agents (csDMARDs) and novel therapies including tumour necrosis factor alpha inhibitors, interleukin 12/23 inhibitor (ustekinumab), the interleukin 17 antagonists including secukinumab, brodalumab, ixekizumab, and the phosphodiesterase-4 inhibitor, apremilast. Areas covered: We reviewed published articles on the treatment of PsA...
November 18, 2016: Expert Review of Clinical Immunology
https://www.readbyqxmd.com/read/27725569/pharmacological-profile-and-clinical-efficacy-of-fully-human-anti-il-17ra-antibody-brodalumab-lumicef-%C3%A2-subcutaneous-injection-210%C3%A2-mg-syringe
#4
Yukiko Aono, Toru Amano, Hiroki Matsudo, Shota Hirose, Takuya Morishige, Natsuko Kikuta, Hiroki Okada, Noriko Hamaura
No abstract text is available yet for this article.
2016: Nihon Yakurigaku Zasshi. Folia Pharmacologica Japonica
https://www.readbyqxmd.com/read/27718760/brodalumab-for-the-treatment-of-psoriasis
#5
M Galluzzo, S D'Adamio, L Bianchi, M Talamonti
Psoriasis is a complex disease in which the alteration of the IL-23/Th17 axis appears to be crucial for its pathogenic mechanisms, and anti-IL17 agents are rapidly becoming important therapeutic tools. Brodalumab, a fully human Chinese hamster ovary cell-derived immunoglobulin G2 (IgG2) anti-IL-17RA monoclonal antibody, is currently the most-developed treatment that binds to the IL-17RA. The authors review and provide updates of efficacy and safety by several studies on brodalumab. Areas covered: A PubMed search was performed for relevant literature...
October 10, 2016: Expert Review of Clinical Immunology
https://www.readbyqxmd.com/read/27687859/a-review-of-emerging-il-17-inhibitors-in-the-treatment-of-psoriasis-focusing-on-preclinical-through-phase-ii-studies
#6
Molly Campa, Alan Menter
INTRODUCTION: Interleukin-17 has recently been identified as a key player in the pathogenesis of psoriasis. As such, several drugs targeting IL-17 are in various stages of clinical development. AREAS COVERED: In this review, the authors describe several emerging therapies and drug candidates targeting IL-17. The authors detail many biologic injectable drug candidates as well as numerous potential oral and topical small molecule drug candidates. EXPERT OPINION: Approval of IL-17 inhibitors has significantly improved the treatment options for psoriasis patients...
September 30, 2016: Expert Opinion on Investigational Drugs
https://www.readbyqxmd.com/read/27672309/efficacy-and-safety-of-monoclonal-antibodies-targeting-interleukin-17-pathway-for-inflammatory-arthritis-a-meta-analysis-of-randomized-controlled-clinical-trials
#7
Min Wei, Dongmei Duan
T-helper 17 (Th17) pathway plays an important and distinct role in autoimmunity and inflammation. A growing body of evidence demonstrates that interleukin-17 (IL-17) is also synthesized in inflammatory arthritis tissues and exerts potent proinflammatory and joint-destructive activities. Clinical studies have been performed to evaluate the therapeutic efficacy of antibodies blocking the IL-17 signaling pathway in patients with rheumatoid arthritis (RA). In this study, we performed a meta-analysis to systematically evaluate the clinical effects of IL-17 antibodies in RA patients...
2016: Drug Design, Development and Therapy
https://www.readbyqxmd.com/read/27660250/erratum-to-brodalumab-first-global-approval
#8
Sarah L Greig
No abstract text is available yet for this article.
September 22, 2016: Drugs
https://www.readbyqxmd.com/read/27605893/interleukin-17-inhibitors-a-new-era-in-treatment-of-psoriasis-and-other-skin-diseases
#9
REVIEW
Agnieszka Wasilewska, Marta Winiarska, Małgorzata Olszewska, Lidia Rudnicka
Psoriasis is a chronic skin disease caused by the excessive secretion of inflammatory cytokines. Available therapeutic options include biologic drugs such as tumor necrosis factor alpha inhibitors and interleukin 12/23 (IL-12/23) inhibitors. The recent discovery of IL-17, which contributes to development of psoriasis, opened new possibilities for further treatment modalities. Currently, one anti-IL17 biological agent is approved for the treatment - a fully human monoclonal antibody that targets IL-17A (secukinumab)...
August 2016: Postȩpy Dermatologii i Alergologii
https://www.readbyqxmd.com/read/27580411/candida-infections-in-psoriasis-and-psoriatic-arthritis-patients-treated-with-il-17-inhibitors-and-their-practical-management
#10
D M Saunte, U Mrowietz, L Puig, C Zachariae
The recognition of the central role of interleukin 17A (IL-17A) in the pathogenesis of psoriasis has led to the development of several monoclonal antibodies targeting this cytokine or its receptors for therapeutic purposes. IL-17A also plays an important role in the immunological protection against infections, especially those due to Candida sp., as evidenced by findings in patients with genetic defects in IL-17 related immune responses. To assess the potential of anti-Il-17 treatment to promote Candida infections, here we have systematically reviewed published clinical trials of patients with psoriasis or psoriatic arthritis...
August 31, 2016: British Journal of Dermatology
https://www.readbyqxmd.com/read/27577550/brodalumab-first-global-approval
#11
Sarah L Greig
Brodalumab (Lumicef(®)) is a human monoclonal immunoglobulin G antibody that is being developed by Kyowa Hakko Kirin in Japan, where it has been approved for the treatment of psoriasis vulgaris, psoriatic arthritis, pustular psoriasis and psoriatic erythroderma. Brodalumab binds with high affinity to interleukin (IL)-17 receptor A, thereby inhibiting several pro-inflammatory cytokines from the IL-17 family. Regulatory applications for brodalumab in plaque psoriasis are also under review in the USA, EU and Canada...
September 2016: Drugs
https://www.readbyqxmd.com/read/27554637/no-meaningful-association-between-suicidal-behavior-and-the-use-of-il-17a-neutralizing-or-il-17ra-blocking-agents
#12
Andrea Chiricozzi, Marco Romanelli, Rosita Saraceno, Tiago Torres
INTRODUCTION: An emerging class of agents blocking IL-17 signaling represents a very promising therapeutic approach. One of these agents, brodalumab, has been associated with an increased risk of suicide behavior. AREAS COVERED: This review sought to provide an overview strictly focused on suicide behavior signals related to the use of IL-17 agents. Data collection regarding this peculiar safety aspect was primarily based on: (i) a revision of safety outcomes belonging to phase II and phase III trials; (ii) a systematic search using the Pubmed Medline database; and (iii) collecting recent data issued as posters or communications in eminent international meetings...
August 31, 2016: Expert Opinion on Drug Safety
https://www.readbyqxmd.com/read/27537993/transitioning-between-brodalumab-and-secukinumab-in-moderate-to-severe-psoriasis-an-early-look
#13
Ronald B Vender
BACKGROUND: Biologics have changed the way we treat moderate to severe psoriasis. Clinical trials for these patients offer the chance for those suffering from psoriasis to volunteer their time for the advancement of science while possibly gaining benefit from the efficacy of these medications.<BR /> OBJECTIVE: All clinical trials have an ending by study design. In the past, trials ended abruptly but it is more common now for transitioning to the approved or another biologic to be offered...
August 1, 2016: Journal of Drugs in Dermatology: JDD
https://www.readbyqxmd.com/read/27535597/brodalumab-established-as-an-effective-interleukin-17-receptor-antagonist-in-psoriasis
#14
A D Ormerod
No abstract text is available yet for this article.
August 2016: British Journal of Dermatology
https://www.readbyqxmd.com/read/27453494/molecularly-targeted-therapies-for-asthma-current-development-challenges-and-potential-clinical-translation
#15
REVIEW
Ibrahim Sulaiman, Jonathan Chee Woei Lim, Hon Liong Soo, Johnson Stanslas
Extensive research into the therapeutics of asthma has yielded numerous effective interventions over the past few decades. However, adverse effects and ineffectiveness of most of these medications especially in the management of steroid resistant severe asthma necessitate the development of better medications. Numerous drug targets with inherent airway smooth muscle tone modulatory role have been identified for asthma therapy. This article reviews the latest understanding of underlying molecular aetiology of asthma towards design and development of better antiasthma drugs...
October 2016: Pulmonary Pharmacology & Therapeutics
https://www.readbyqxmd.com/read/27358210/long-term-clinical-safety-and-efficacy-of-brodalumab-in-the-treatment-of-japanese-patients-with-moderate-to-severe-plaque-psoriasis
#16
Y Umezawa, H Nakagawa, H Niiro, K Ootaki
BACKGROUND: Brodalumab (KHK4827) is a human anti-interleukin-17-receptor A monoclonal antibody. In Japanese patients with moderate-to-severe plaque psoriasis, brodalumab showed rapid and robust efficacy and a favourable safety profile in a 12-week, phase 2, double-blind, randomized controlled trial. OBJECTIVES: To evaluate the long-term safety and efficacy of brodalumab, an extension of a phase 2 trial of Japanese patients with moderate-to-severe psoriasis was performed...
June 29, 2016: Journal of the European Academy of Dermatology and Venereology: JEADV
https://www.readbyqxmd.com/read/27221323/brodalumab-for-the-treatment-of-psoriasis-a-review-of-phase-iii-trials
#17
REVIEW
Benjamin Farahnik, Kourosh Beroukhim, Michael Abrouk, Mio Nakamura, Tian Hao Zhu, Rasnik Singh, Kristina Lee, Tina Bhutani, John Koo
INTRODUCTION: Interleukin (IL)-17 inhibitors are the most recent class of monoclonal antibodies approved by the FDA for psoriasis treatment. Preclinical and phase II studies of brodalumab, a high-affinity IL-17 receptor monoclonal antibody, have been encouraging. METHODS: We conducted a literature search using the PubMed database in order to assess the efficacy and safety profile of brodalumab. The search included the following key words: "psoriasis" and "IL-17" or "brodalumab...
June 2016: Dermatology and Therapy
https://www.readbyqxmd.com/read/27207350/the-role-of-il-17-in-the-pathogenesis-of-psoriasis-and-update-on-il-17-inhibitors-for-the-treatment-of-plaque-psoriasis
#18
Mohn'd AbuHilal, Scott Walsh, Neil Shear
BACKGROUND: Major advances have been made in the understanding of the pathophysiology of psoriasis. OBJECTIVES: The authors review the role of interleukin (IL) 17 in the pathogenesis of psoriasis and provide updates on approved and investigational therapies targeting IL-17 and the IL-17 receptor. METHODS: A PubMed search was performed for relevant literature. CONCLUSION: The IL-23/Th17 signaling pathway (including IL-17) plays a central role in the pathogenesis of psoriasis...
May 20, 2016: Journal of Cutaneous Medicine and Surgery
https://www.readbyqxmd.com/read/27106510/efficacy-and-safety-of-brodalumab-in-patients-with-generalized-pustular-psoriasis-and-psoriatic-erythroderma-results-from-a-52-week-open-label-study
#19
K Yamasaki, H Nakagawa, Y Kubo, K Ootaki
BACKGROUND: A T-helper (Th) cell subset Th17 preferentially produces interleukin (IL)-17 and plays a pivotal role in the pathogenesis of psoriasis. However, the pathological roles of IL-17 cascades in generalized pustular psoriasis (GPP) and psoriatic erythroderma (PsE) have not been well established. OBJECTIVES: To evaluate the efficacy and safety of brodalumab, a human immunoglobulin G2 monoclonal antibody against human IL-17-receptor A (IL-17RA), in Japanese patients with GPP and PsE...
April 23, 2016: British Journal of Dermatology
https://www.readbyqxmd.com/read/27105880/anti-il-17-therapy-in-treatment-of-rheumatoid-arthritis-a-systematic-literature-review-and-meta-analysis-of-randomized-controlled-trials
#20
Sumit Kunwar, Khagendra Dahal, Sharan Sharma
IL-17 has a role in inflammation in RA, and its levels in joints correlate with disease severity. Multiple RCTs have been performed to study effects of anti-IL-17 agents. The objective of this study was to perform a systematic review and meta-analysis to analyze the efficacy and safety of anti-IL-17 agents in the management of RA. This work is based on a systematic review of studies retrieved by a sensitive search strategy in PubMed, EMBASE and Cochrane CENTRAL from inception through 9/7/15. Study selection criteria were the following: adult patients (age ≥ 18 years) with RAs, random selection of patients for anti-IL-17 therapy and treatment response compared to placebo...
August 2016: Rheumatology International
keyword
keyword
16491
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"